Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Rosiglitazone142 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A36699 | 17436085 | Dig Dis Sci | Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis. | 2007 | Details |
| A37322 | 15959406 | Ann Endocrinol (Paris) | [Nonalcoholic steatohepatitis]. | 2005 | Details |
| A37543 | 15457967 | Ther Umsch | [Alcoholic and non-alcoholic steatohepatitis]. | 2004 | Details |
| A37568 | 15343508 | Hum Pathol | Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. | 2004 | Details |
| A37708 | 15066643 | Eur J Intern Med | Non-alcoholic steatohepatitis: review of a growing medical problem. | 2004 | Details |
| A37835 | 14512888 | Hepatology | Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. | 2003 | Details |
| A37963 | 12663234 | J Hepatol | Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. | 2003 | Details |
| A38179 | 11965828 | Int J Clin Pract Suppl | Thiazolidinedione hepatotoxicity: a class effect? | 2000 | Details |
| A42908 | 33142057 | J Med Chem | A Novel N-Substituted Valine Derivative with Unique Peroxisome Proliferator-Activated Receptor γ Binding Properties and Biological Activities. | 2020 | Details |
| A45385 | 24879802 | J Lipid Res | Arachidonic acid downregulates acyl-CoA synthetase 4 expression by promoting its ubiquitination and proteasomal degradation. | 2014 | Details |
| A45611 | 23680744 | Hosp Pract (1995) | Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. | 2013 | Details |
| A45675 | 23322813 | Environ Health Perspect | Transgenerational inheritance of increased fat depot size, stem cell reprogramming, and hepatic steatosis elicited by prenatal exposure to the obesogen tributyltin in mice. | 2013 | Details |
| A45786 | 22751293 | Pol Arch Med Wewn | Comment on "Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease". | 2012 | Details |
| A45938 | 21953015 | Hepatology | Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials? | 2011 | Details |
| A46231 | 20156580 | Int J Biochem Cell Biol | Peroxisome proliferator-activated receptors gamma reverses hepatic nutritional fibrosis in mice and suppresses activation of hepatic stellate cells in vitro. | 2010 | Details |
| A46520 | 18046722 | Hepatology | Effects of rosiglitazone on methionine-choline deficient diet-induced nonalcoholic steatohepatitis. | 2007 | Details |
| A46587 | 17429734 | Dig Dis Sci | The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease. | 2007 | Details |
| A46645 | 16932311 | Nat Clin Pract Endocrinol Metab | Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance. | 2006 | Details |
| A46690 | 16510031 | Curr Gastroenterol Rep | New treatments for nonalcoholic fatty liver disease. | 2006 | Details |
| A46743 | 15989845 | Med Clin (Barc) | [Medical management of primary nonalcoholic fatty liver disease]. | 2005 | Details |
| A46781 | 15611492 | Ann Intern Med | Narrative review: hepatobiliary disease in type 2 diabetes mellitus. | 2004 | Details |
| A46802 | 15262299 | Endocrinol Metab Clin North Am | Glitazones and the management of insulin resistance: what they do and how might they be used. | 2004 | Details |
| A47960 | 28098353 | J Cell Physiol | The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice. | 2017 | Details |
| A48238 | 19013165 | Gastroenterology | Rosiglitazone for nonalcoholic steatohepatitis. | 2008 | Details |
| A48289 | 21960831 | Gastroenterol Hepatol (N Y) | Multifocal nodular nonalcoholic steatohepatitis: resolution with rosiglitazone. | 2007 | Details |
| A48341 | 16128278 | Pol Arch Med Wewn | [Effect of high-fat diet, rosiglitazone on lipid profile, insulin resistance and liver steatosis development]. | 2005 | Details |
| A48369 | 14720447 | Curr Gastroenterol Rep | Treatment of nonalcoholic steatohepatitis. | 2004 | Details |
| A48392 | 12663460 | Diabetes | Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. | 2003 | Details |
| A49027 | 20969493 | Scand J Gastroenterol | Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice. | 2010 | Details |
| A49080 | 18752754 | Zhonghua Gan Zang Bing Za Zhi | [Effect of rosiglitazone in non-alcoholic steatohepatitis associated liver fibrosis]. | 2008 | Details |
| A49095 | 18022724 | J Hepatol | Rosiglitazone: possible complications and treatment of non-alcoholic steatohepatitis (NASH). | 2007 | Details |
| A49192 | 14585066 | Expert Opin Drug Saf | Hepatotoxicity of thiazolidinediones. | 2003 | Details |
| A49394 | 35765391 | Cureus | The Role of Thiazolidinediones in the Amelioration of Nonalcoholic Fatty Liver Disease: A Systematic Review. | 2022 | Details |
| A50957 | 35520738 | RSC Adv | GVS-12 attenuates non-alcoholic steatohepatitis by suppressing inflammatory responses via PPARγ/STAT3 signaling pathways. | 2019 | Details |
| A52064 | 31706843 | Biochem Pharmacol | Tetrahydrocannabinolic acid A (THCA-A) reduces adiposity and prevents metabolic disease caused by diet-induced obesity. | 2019 | Details |
| A52095 | 31308847 | PPAR Res | Short-Term Activation of Peroxisome Proliferator-Activated Receptors α and γ Induces Tissue-Specific Effects on Lipid Metabolism and Fatty Acid Composition in Male Wistar Rats. | 2019 | Details |
| A52162 | 30551378 | Biomed Pharmacother | A novel recombinant peptide INSR-IgG4Fc (Yiminsu) restores insulin sensitivity in experimental insulin resistance models. | 2018 | Details |
| A52570 | 25487878 | Sci Rep | Protopanaxatriol, a novel PPARγ antagonist from Panax ginseng, alleviates steatosis in mice. | 2014 | Details |
| A52751 | 22471957 | Cardiovasc Hematol Agents Med Chem | PPAR- γ agonist in treatment of diabetes: cardiovascular safety considerations. | 2012 | Details |
| A53039 | 16750656 | Vascul Pharmacol | Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of type 2 diabetes: relation to dysregulated phosphatidylcholine metabolism. | 2006 | Details |
| A53055 | 16339123 | Obes Res | (+)-Z-Bisdehydrodoisynolic acid ameliorates obesity and the metabolic syndrome in female ZDF rats. | 2005 | Details |
| A53064 | 16088969 | Diabetes Metab Res Rev | Prevention of nutritionally induced diabetes by rosiglitazone in the gerbil Psammomys obesus. | 2006 | Details |